Guidelines for Titrating Off Omeprazole

Initial Assessment

• Patients should only be considered for omeprazole discontinuation when there is no strong ongoing indication for proton‑pump inhibitor (PPI) therapy, such as severe esophagitis, Barrett’s esophagus, or high risk of upper‑GI bleeding. The Gastroenterology Society advises confirming the absence of these contraindications before de‑prescribing. 1

Discontinuation Strategies

• Abrupt cessation – Stop omeprazole immediately without any tapering schedule. This approach is endorsed as an acceptable option. 1
• Dose tapering (3‑week protocol) – Reduce dosing to every‑other‑day for weeks 1–3, then discontinue completely after week 3. This regimen is also considered acceptable. 1
• Comparative effectiveness – Success rates at 6 months were similar between abrupt discontinuation (31 % remaining off PPIs) and tapering (22 % remaining off PPIs); no statistically significant difference was observed. 1
• Evidence interpretation – Current data do not demonstrate clear superiority of tapering over abrupt cessation; the 3‑week taper may be too rapid to fully prevent rebound acid hypersecretion because parietal‑cell hyperplasia can require 2–6 months to regress. 1

Managing Post‑Discontinuation Symptoms

• Rebound acid hypersecretion (RAHS) – Patients should be warned that temporary upper‑GI symptoms are common after stopping long‑term PPI therapy due to RAHS. These symptoms may persist for up to 8 weeks, while parietal‑cell mass typically regresses by 6 months. The presence of symptoms does not automatically indicate a need to resume continuous PPI therapy. 1
• Symptom‑control alternatives – For breakthrough symptoms, the following non‑continuous strategies are recommended:
  
  • H₂‑receptor antagonists (e.g., famotidine) on an as‑needed basis.
  • Over‑the‑counter antacids for immediate neutralization.
  • On‑demand PPI dosing (taking a dose only when symptomatic).

Follow‑Up and Re‑evaluation

• Early reassessment – Evaluate patients 4–8 weeks after discontinuation to determine symptom trajectory.
• Persistent severe symptoms – If severe symptoms continue beyond 2 months, consider that a true ongoing need for PPI therapy may exist or that a non‑acid‑mediated cause warrants further investigation. 1

Clinical Pearls

• Approximately three‑quarters of patients who successfully discontinue PPIs continue to use H₂‑receptor antagonists or antacids for occasional symptom relief. 1

Strength of evidence: All statements are derived from a single 2022 Gastroenterology Society guideline; the document does not specify a formal grading system, so the evidence level is considered moderate based on expert consensus and observational data.

De-prescribing Proton Pump Inhibitors (PPIs) in Patients with Gastroesophageal Reflux Disease (GERD)

Introduction to De-prescribing

• The American Gastroenterological Association recommends that all patients using PPIs should undergo routine evaluation of ongoing indications, and patients without a definitive indication for chronic use should be considered for a de-prescribing trial 2, 3

Patient Selection for De-prescribing

• Patients without a definitive indication for chronic PPI use should be considered for a de-prescribing trial, as PPIs can only pose harm, including pill burden, medication costs, and potential side effects, in the absence of a clear benefit 2
• The majority of patients with GERD have non-erosive disease, making them ideal candidates for de-prescribing 2
• Patients using twice-daily doses of PPIs should be considered for dose reduction to once daily, as high-dose PPI use is not FDA-approved and has not been studied in randomized controlled trials (RCTs) 2, 4

Contraindications to De-prescribing

• Patients with complicated GERD, such as a history of severe erosive esophagitis (LA grade C/D), esophageal ulcers, or peptic stricture, should not be considered for PPI de-prescribing 4, 5
• Patients with Barrett's esophagus, eosinophilic esophagitis, or idiopathic pulmonary fibrosis should not be considered for PPI de-prescribing 4, 6
• Patients with a high risk of upper gastrointestinal bleeding should not be considered for PPI de-prescribing 4, 5

Risk Assessment for De-prescribing

• Patients should be assessed for their risk of upper gastrointestinal bleeding using an evidence-based strategy before de-prescribing PPIs 4, 5
• Evaluation of risk factors, such as anticoagulant, antiplatelet, or NSAID use, history of peptic ulcer disease, or previous gastrointestinal bleeding, should be performed before de-prescribing PPIs 4

De-prescribing Strategies

• Both tapering and abrupt discontinuation of PPIs can be considered when de-prescribing, although evidence is limited 7, 4, 5
• Patients who discontinue long-term PPI therapy should be informed that they may experience temporary upper gastrointestinal symptoms due to rebound acid hypersecretion 7, 4, 5

Follow-up After De-prescribing

• Patients should be re-evaluated for symptoms 4-8 weeks after a de-prescribing trial, and if symptoms recur and are bothersome, consideration should be given to restarting PPIs at the lowest effective dose 8
• For patients with GERD who have not been proven to respond to empirical PPI therapy, consideration should be given to endoscopy with prolonged reflux monitoring off PPIs within 12 months to determine the appropriateness of long-term PPI therapy 8

Discontinuation Strategies for Dexlansoprazole After H. pylori Eradication

Guideline Recommendations (American Gastroenterological Association, 2022)

Evidence from Randomized Trial

Practical Discontinuation Steps

Managing Rebound Acid Hypersecretion (RAHS)

• Famotidine (H₂‑receptor antagonist) 12
• Over‑the‑counter antacids 12
• On‑demand PPI dosing (only when symptomatic) 12

Follow‑Up and Indications for Re‑initiation

Criteria for Continuing PPIs After H. pylori Eradication

Key Pitfall to Avoid